source
- Dutch court blocks Merck's subcutaneous Keytruda in several European marketsA Dutch court has ruled that Merck infringed a patent covering a subcutaneous formulation of its cancer drug Keytruda. The decision requires the company to stop manufacturing and marketing that ver…
- Novartis-partnered Matchpoint Therapeutics raises $150 million Series B to fund clinical entryMatchpoint Therapeutics, a biotech company working with Novartis, announced the close of a new financing round. The round raised $150 million in Series B funding. The capital will be used to advan…